$EIKN

Eikon Therapeutics, Inc.

Eikon Therapeutics is a clinical biopharmaceutical company developing medicines, with an initial focus on oncology and additional discovery research in neurologic disease. It uses a technology platform centered on proprietary single molecule tracking, alongside artificial intelligence and machine learning tools, to support drug discovery and development. Its pipeline includes EIK1001, an immune-stimulating TLR 7/8 dual-agonist; the selective PARP1 inhibitors EIK1003 and EIK1004; EIK1005, a WRN helicase inhibitor; and EIK1006, an androgen receptor antagonist. EIK1001, EIK1003, EIK1004 and EIK1005 are in clinical trials, while EIK1006 is in preclinical studies. Eikon develops internally derived candidates and also expands its pipeline by in-licensing drug candidates from other companies. Its programs target cancers including melanoma, non-small cell lung, ovarian, breast, prostate and pancreatic cancers. Eikon is headquartered in Millbrae, California.

3
2
1

No SEC Form 4 filings for $EIKN in the last 30 days.

See all $EIKN insider activity →
Med

Eikon gets FDA clearance for prostate cancer drug trial

Eikon Therapeutics (EIKN) received FDA clearance for its prostate cancer drug EIK1006, advancing to Phase 1/2 trials. The study, ARGATE-001, will assess safety and efficacy in metastatic prostate cancer patients resistant to standard therapies. Dosing is expected to start in 2027, with preliminary data by late 2027. EIK1006 targets androgen receptor pathway alterations, a common cause of treatment resistance.

Eikon Therapeutics Reports $86.1 Million Q3 Net Loss, $461.7 Million in Cash

Eikon Therapeutics reported a Q3 2026 net loss of $86.1M, up from $71.1M a year earlier. Cash reserves totaled $461.7M. R&D expenses rose to $71.8M. The company reported clinical progress in its oncology pipeline, including NSCLC and prostate cancer trials. EIK1001 showed a 63.1% response rate in NSCLC. Eikon plans to initiate a Phase 1/2 study for EIK1006, pending FDA clearance.

Eikon Therapeutics Reports Third Quarter 2026 Financial Results

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from

EIKN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning EIKN (Eikon Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 1 bearish.

Recent EIKN coverage spans earnings, technology and financial news.

What's driving EIKN

AlphAI scores every news story that mentions EIKN with an AI model for sentiment and relevance, and aggregates insider trades from Eikon Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EIKN

Score
$EIKNMedAI 8/10

Eikon gets FDA clearance for prostate cancer drug trial

Eikon Therapeutics (EIKN) received FDA clearance for its prostate cancer drug EIK1006, advancing to Phase 1/2 trials. The study, ARGATE-001, will assess safety and efficacy in metastatic prostate cancer patients resistant to standard therapies. Dosing is expected to start in 2027, with preliminary data by late 2027. EIK1006 targets androgen receptor pathway alterations, a common cause of treatment resistance.

Eikon Therapeutics Reports $86.1 Million Q3 Net Loss, $461.7 Million in Cash

Eikon Therapeutics reported a Q3 2026 net loss of $86.1M, up from $71.1M a year earlier. Cash reserves totaled $461.7M. R&D expenses rose to $71.8M. The company reported clinical progress in its oncology pipeline, including NSCLC and prostate cancer trials. EIK1001 showed a 63.1% response rate in NSCLC. Eikon plans to initiate a Phase 1/2 study for EIK1006, pending FDA clearance.

$EIKNMedAI 8/10Earnings

Eikon Therapeutics Reports Third Quarter 2026 Financial Results

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from

Eikon Therapeutics, Inc. (EIKN) Expects Cash Runway Into Q1 2028

Eikon Therapeutics (EIKN) reported $461.7M in cash as of Q3 2026, expecting it to last into Q1 2028. The company presented clinical data at ESMO Congress, dosed the first patient in a Phase 2/3 trial, and submitted an IND application for a prostate cancer drug. Q3 2026 net loss widened to $86.1M from $71.1M a year earlier, with R&D expenses rising 21% to $71.8M.

Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029

Eikon Therapeutics (NASDAQ:EIKN) reported progress in its melanoma trial, expecting key data in 2029. The company also discussed its PARP1 inhibitors, EIK1003 and EIK1004, showing promising early results in combination therapies. Eikon's pipeline includes a Werner helicase inhibitor and an androgen receptor antagonist, with patient enrollment expected soon for the latter. The company aims to leverage its live-cell imaging technology for drug discovery in oncology and other serious diseases.

$EIKNHighAI 9/10Clinical / regulatory· topline data

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress • TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable e

Eikon Therapeutics Reports ESMO Data Across PARP1 and WRN Programs

Eikon Therapeutics (EIKN) presented clinical data for its EIK1003, EIK1004, and EIK1005 programs, showing antitumor activity and manageable safety profiles. EIK1003 monotherapy had a 14.3% overall response rate, higher among PARP-inhibitor-naïve participants. Combinations with abiraterone and paclitaxel showed preliminary activity. EIK1004 had a 12.1% response rate with minimal severe toxicities. EIK1005 monotherapy resulted in stable disease for most participants.

$EIKNHighAI 8/10Clinical / regulatory· topline data

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress • Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 contin

Related tickers